Dr. Shi Jin 金时
Chief Physician
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of lung cancer, including chemotherapy, targeted therapy, and immunotherapy. Expertise in early differentiation and follow-up of small lung nodules, as well as pain management.
Dr. Jin is a Chief Physician and postdoctoral researcher with 13 years of clinical experience. A former visiting scholar at MD Anderson Cancer Center, Dr. Jin focuses on clinical translational research in solid tumor immunotherapy. Previously served as Deputy Director of the Respiratory Tumor Ward at Harbin Medical University Cancer Hospital. Has published over 30 papers and led multiple national and provincial research projects.
Professional roles
- Member, Youth Committee of Tumor Metastasis Professional Committee, China Anti-Cancer Association
- Chair, Youth Committee of Tumor Palliative Care Committee, Heilongjiang Anti-Cancer Association
- Youth Committee Member, Lung Cancer Professional Committee, China Medical Education Association
- Standing Committee Member, Lung Cancer Professional Committee, Heilongjiang Medical Doctor Association
Name order: in Chinese the family name comes first (Jin Shi). Papers usually list the name as Shi Jin or Jin S.
Selected publications
32 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Surg, 2025 (senior author): Radiomic phenotypes and tumor immunobiology: advancing NSCLC immunotherapy prediction through unsupervised learning and digital integration (correspondence). PubMed 41255295
- Int J Surg, 2025 (senior author): Integrating explainable AI and digital twins for next-generation therapeutic stratification in oncology (Correspondence). PubMed 41208618
- Heliyon, 2024 (senior author): Investigation of RBM10 mutation and its associations with clinical and molecular characteristics in EGFR-mutant and EGFR-wildtype lung adenocarcinoma. PubMed 38912481
- Aging (Albany NY), 2023 (senior author): Cathepsin V drives lung cancer progression by shaping the immunosuppressive environment and adhesion molecules cleavage. PubMed 38078882
- Oxid Med Cell Longev, 2022 (senior author): RBM10 Is a Biomarker Associated with Pan-Cancer Prognosis and Immune Infiltration: System Analysis Combined with In Vitro and Vivo Experiments. PubMed 39282149
- Transl Cancer Res, 2022 (senior author): Efficacy of osimertinib in a metastatic lung adenocarcinoma patient harboring somatic EGFR delL747_S752 and germline BIM deletion polymorphism: a case report and literature review. PubMed 36388025
- Front Mol Biosci, 2021 (senior author): Clinical Associations of Preoperative and Postoperative Serum CEA and Lung Cancer Outcome. PubMed 34778369
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion